IL-6 facilitates the acute phase response (raising CRP) and can modulate pain pathways; in fact, an IL-6 blocker (tocilizumab) has shown some benefit in cluster headache, hinting at a role in cranial pain disorders. This evidence concerns the gene IL6 and Cluster headache.